A study of PRJ1-3024 for advanced or spreading melanoma
Part of Cancer, Skin clinical trials.
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma that cannot be removed by surgery or has spread to other parts of the body
- You have tried at least one standard treatment and it stopped working
- You are at least 18 years old and able to take oral medications
- You have a life expectancy of 3 months or more
- You have adequate organ function (liver, kidneys, and blood cells)
- You do not have certain other medical conditions like autoimmune disease or active infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called IBI363 for people with advanced melanoma that has progressed after standard treatment. It aims to see if IBI363 can shrink tumors or slow their growth.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
This early-phase trial studies a combination treatment—an interferon-type medicine, an immune checkpoint antibody, and a targeted anti-angiogenesis pill—for advanced melanoma that cannot be removed with surgery. The goal is to see whether this combination can shrink tumors and be tolerated, and to learn the best way to treat this stage of melanoma.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.